Asthma immunopathogenesis and biomarkers in asthma treatment

Abstract

Asthma is a disease that affects millions of people all over the world. In terms of socio-economic status, especially low and medium-level countries are more affected by this situation. Intestinal and lung microbiota play an important role in the basis of the disease. In previous years, the paradigm between Th1 and Th2 was thought to be responsible for airway inflammation in asthma. But over the years, Treg and Th17 cells, which are subgroups of these cells, have been discovered, unlike Th1 and Th2 cells. It was thought that the connection between these cells may also be an effective factor in asthma. In the following years, it was possible to gain knowledge by using factors such as onset of symptoms, presentation of symptoms, allergy, eosinophil and disease severity in determining phenotypes. Today's biotechnological developments are increasing rapidly. In this way, there are developments in the field of targeted therapy.